- Original Release Date:
July 2008
-
Expiration Date: July 2010
- Estimated Time to Complete this
Educational Activity: 1.5 hours
-
Type of Enduring Material: Internet-Based CE
- DISCLAIMER:
The views and observations presented in this
Continuing Education publication are those of the
authors/editors and do not necessarily reflect those of the funders or producers of this publication. Readers are urged
to consult current prescribing and clinical practice
information in any drug, device or procedure discussed in
this publication.
LEARNING OBJECTIVES
After completing this Clinical Updates
you will be able to:
- Describe the action of bisphosphonate
drugs on bone
- Compare the effectiveness of various
FDA-approved bisphosphonates available for prevention and
treatment of osteoporosis
- Cite the circumstances under which it is
appropriate to consider a “drug holiday” from bisphosphonate
treatment
- Discuss potential osteoporosis treatment
plans tailored to fit particular patient profiles
- Explain the criteria for assessing
patient response to bisphosphonate treatment
DISCLOSURE INFORMATION
It is the policy of NOF to ensure balance, independence,
objectivity, and scientific rigor in all its sponsored
publications and programs. NOF requires the disclosure of the
existence of any significant financial interest or any other
relationship the sponsor, Editorial Board or Guest Faculty
members have with the manufacturer(s) of any commercial
product(s) discussed in an educational presentation. All authors
and contributors to this continuing education activity have
disclosed any real or apparent commercial interest that may have
direct bearing on the subject matter of this activity. EDITORIAL
BOARD MEMBER DISCLOSURES
Editor-in-Chief
Angelo Licata, MD, PhD, FACP, FACE
Research Support
Merck, Lilly, Aventis, Novartis, NPS Pharmaceuticals, Procter &
Gamble
Speaker
Lilly, Aventis, Procter & Gamble
Senior Editorial Consultant
Lawrence G. Raisz, MD
Research Support
Servier Pharmaceuticals
Consultant
Pfizer Laboratories, Procter & Gamble, Colgate Palmolive,
Novartis
Members
Adrienne Berarducci, PhD, ARNP, BC, CCD
Grant/Research Support
Procter & Gamble Pharmaceuticals
Speakers Bureau
Procter & Gamble Pharmaceuticals
Carolyn J. Bolognese, RN
No relationships to disclose
Peggy Doheny, PhD, RN, ONC
No relationships to disclose
Vernon Herschberger, MD, ABFM
Consultant
Roche Diagnostics
Speakers Bureau
Novartis
Research Support
GlaxoSmithKline, Wyeth
Barbara Lukert, MD, FACP
Speakers Bureau
Merck, Proctor & Gamble, Eli Lilly
Paul D. Miller, MD
Research Support
Procter & Gamble, Aventis Pharmaceuticals, Roche
Pharmaceuticals, Eli Lilly, Pharmacia, Merck & Co., Novartis,
Pfizer, Amgen
Advisory and Speaker Boards
Procter & Gamble, Aventis, Merck, Lilly
Jeri Nieves, PhD
No relationships to disclose
Carol Sedlak, PhD, RN, ONC
No relationships to disclose
Kathy M. Shipp, PhD, PT, MHS
No relationships to disclose
Holly Thacker, MD, FACP
No relationships to disclose
NOF STAFF DISCLOSURES
Felicia Cosman, MD
Speakers Bureau
Eli Lilly, Merck
Advisory Board
Eli Lilly, Merck, Novartis, NPS Pharmaceuticals
Susan Randall, RN, MSN, FNP-BC
No relationships to disclose
Audrey Shively, MSHSE, CHES
No relationships to disclose
Kelly Trippe, MA
No relationships to disclose.
Click Here for Article
Click Here for
Self-Assessment
Software Requirement:
Adobe Acrobat Reader is required to read the text for this
continuing education activity.
If you do not have Adobe Acrobat Reader,
click
here.
|
